EyePoint Pharmaceuticals Inc (NAS:EYPT)
$ 11.13 -0.03 (-0.27%) Market Cap: 579.70 Mil Enterprise Value: 286.54 Mil PE Ratio: 0 PB Ratio: 2.22 GF Score: 55/100

Q2 2020 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Aug 05, 2020 / 12:30PM GMT
Release Date Price: $6.93 (-5.03%)
Operator

Good morning. My name is Josh, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Second Quarter 2020 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to George Elston, Chief Financial Officer of EyePoint Pharmaceuticals.

George O. Elston
EyePoint Pharmaceuticals, Inc. - CFO & Head of Corporate Development

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' Second Quarter 2020 Financial Results and recent Corporate Developments. With me today is Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Strategic Scientific Officer; and Scott Jones, Chief Commercial Officer. Nancy will begin with a review of recent corporate updates, including our new commercial alliance with ImprimisRx that we announced yesterday. Dr. Duke will then discuss pipeline developments for EYP-1901 and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot